Drug pricing watchdog says there’s ‘insufficient’ evidence that Biogen’s Alzheimer’s medicine would help patients

Abstract: In a draft report, Boston-based ICER cites conflicting data from two trials. The Cambridge biotech says it “does not accurately reflect the possible holistic value” of the experimental treatment.